2-methyl-thieno-benzodiazepine
AssigneeLilly Industries Limited
InventorsJiban K. Chakrabarti, Terrence M. Hotten, David E. Tupper
Life of this patent
Estimating the term…
Abstract
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Claims10
A method of treating a patient suffering from or susceptible to psychosis selected from the group consisting of Schizophrenia, Catatonic, Subchronic;
- Schizophrenia, Catatonic, Chronic;
- Schizophrenia, Catatonic, Subchronic with Acute Exacerbation;
- Schizophrenia, Catatonic, Chronic with Acute Exacerbation;
- Schizophrenia, Catatonic, in Remission;
- Schizophrenia, Catatonic, Unspecified;
- Schizophrenia, Disorganized, Subchronic;
- Schizophrenia, Disorganized, Chronic;
- Schizophrenia, Disorganized, Subchronic with Acute Exacerbation;
- Schizophrenia, Disorganized, Chronic with Acute Exacerbation;
- Schizophrenia, Disorganized, in Remission;
- Schizophrenia, Disorganized, Unspecified;
- Schizophrenia, Paranoid, Subchronic;
- Schizophrenia, Paranoid, Chronic;
- Schizophrenia, Paranoid, Subchronic with Acute Exacerbation;
- Schizophrenia, Paranoid, Chronic with Acute Exacerbation;
- Schizophrenia, Paranoid, in Remission;
- Schizophrenia, Paranoid, Unspecified;
- Schizophrenia, Undifferentiated, Subchronic;
- Schizophrenia, Undifferentiated, Chronic;
- Schizophrenia, Undifferentiated, Subchronic with Acute Exacerbation;
- Schizophrenia, Undifferentiated, Chronic with Acute Exacerbation;
- Schizophrenia, Undifferentiated, in Remission;
- Schizophrenia, Undifferentiated, Unspecified;
- Schizophrenia, Residual, Subchronic;
- Schizophrenia, Residual, Chronic;
- Schizophrenia, Residual, Subchronic with Acute Exacerbation;
- Schizophrenia, Residual, Chronic with Acute Exacerbation;
- Schizophrenia, Residual, in Remission;
- Schizophrenia, Residual, Unspecified;
- Delusional (Paranoid) Disorder;
- Brief Reactive Psychosis;
- Schizophreniform Disorder;
- Schizoaffective Disorder;
- Induced Psychotic Disorder;
- Psychotic Disorder NOS (Atypical Psychosis);
- Bipolar Disorder, Mixed, with Psychotic Features;
- Bipolar Disorder, Manic, with Psychotic Features;
- Bipolar Disorder, Depressed, with Psychotic Features;
- and Major Depression, Single Episode, with Psychotic Features;
- comprising administering to a patient in need thereof an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, acid addition salt thereof.
A method of treating a patient suffering from or susceptible to an anxiety disorder selected from the group consisting of Psychoactive Substance Anxiety Disorder;
- Organic Anxiety Disorder;
- Obsessive Compulsive Disorder;
- Post-traumatic Stress Disorder;
- Generalized Anxiety Disorder;
- and Anxiety Disorder NOS;
- comprising administering to a patient in need thereof an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof.
A method of treating a patient suffering from or susceptible to a pathologic psychological condition wherein delusions, hallucinations, disorganized behavior, or anxiety are a consistent manifestation of the pathologic condition, comprising administering to a patient in need thereof an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof.
Dependencies are inferred from the claim text.